BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction
22 mars 2022 05h00 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
Invea Therapeutics Announces Poster Presentations at Keystone Symposia Gut-Brain Axis and Digestive Disease Week (DDW2022)
17 mars 2022 08h10 HE
|
Invea Therapeutics
GUILFORD, Conn., March 17, 2022 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc., a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and...
BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members
17 févr. 2022 17h42 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
24 janv. 2022 15h52 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
10 janv. 2022 07h30 HE
|
InflaRx N.V.
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:...
Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response
28 sept. 2021 11h17 HE
|
BioAegis Therapeutics
This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype. NORTH BRUNSWICK, New Jersey, Sept. 28, 2021 (GLOBE NEWSWIRE) --...
Ulcerative Colitis Clinical Landscape Report 2021: Pipeline Holds Multiple Novel Prospects in Terms of Distinct Mechanisms of Action and Biologics
12 juil. 2021 05h33 HE
|
Research and Markets
Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Ulcerative Colitis" report has been added to ResearchAndMarkets.com's offering. UC typically presents with bloody diarrhea, which may...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
29 juin 2021 13h58 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
24 juin 2021 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on...
Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
08 avr. 2021 18h58 HE
|
BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell...